The US Federal Trade Commission found that only one patent settlement agreement between brand and generic companies in fiscal year 2016 contained a side deal or commitment not to market an authorized generic, suggesting that so-called pay-for-delay deals may become a thing of the past.
In its latest report on brand-generic patent settlements, released on 23 May, the FTC does not use the term...







